Corcept's sales jumped from Q2. Its cancer launch explains half.
Corcept has two sources of growth behind its strong quarter. Our calculation separates the Lifyorli launch from the older products and tests the unchanged annual sales range.
Ticker Byline
Earnings & Outlook · Page 3
Page 3. Quarterly results, changing forecasts and the operating trends behind company performance.
Unum's new profit measure gets a boost. Its forecast still falls.
Unum lowered its profit forecast after changing its adjusted earnings measure. Our comparison finds a worsening disability claims ratio beyond the reserve adjustments.
Ashland's new profit target rests on an unfinished factory recovery
Ashland met the low end of its annual EBITDA range but missed its EPS growth forecast. Our comparison shows where profit improvement stalled and what the new plan requires.
Dynatrace's strong quarter comes with a lower annual profit target
Dynatrace beat its quarterly forecast, then lowered its annual adjusted-profit target after buying Arize. Our comparison shows what the new outlook implies for the second half.
Duolingo is dropping Max. Its growth bet moves to Super.
Duolingo will stop selling new Max subscriptions as Video Call expands to Super. Our forecast comparison shows how much of its annual forecast increase was already earned in Q3.
Vertex raised its sales forecast. Its spending budget rose faster.
Vertex raised its annual revenue outlook after closing Crinetics, but its spending forecast increased more. Our comparison explains what the earlier outlook excluded and how profit and funding changed.
People Inc.'s web visits fell 25%. Why did digital revenue rise?
People Incorporated's publisher grew digital revenue despite a steep decline in visits. Our document comparison shows how licensing offset lost advertising and why adjusted publishing profit still fell.
Clorox's sales jumped 33%. Why did its gross margin fall?
Clorox's sales rebound comes with a lower gross margin and annual adjusted earnings expectations near the bottom of an unchanged range. Our comparison explains the inventory effect and the cost pressure.
Adeia's new sales ceiling is its old midpoint
Adeia cut both ends of its annual revenue forecast by $20 million. Our comparison shows how the new ceiling, lower cost budget and cash results change the picture.
Metallus has a $125 million defense order. Why does Q4 look weaker?
Metallus' aerospace and defense growth contrasts with a weaker Q4 profit outlook. Our calculations show the source of the sales gain and what the annual target leaves for the final quarter.
Tinder hit its usage milestone. Can Match bring back paying users?
Tinder reached its September usage milestone, but paying users are still falling. Our comparison examines Hinge's offset, weakness at smaller brands and the marketing shift behind Match's adjusted profit beat.
Inspire expects a rebound before its new billing codes arrive
Inspire expects modest growth in 2027, ahead of new billing codes in 2028. Our comparison examines the unchanged annual sales midpoint and the profit pressure beyond restructuring.
Celanese's cash surge includes a $184 million timing boost
Celanese generated $461 million of quarterly free cash flow. Our comparison explains the working-capital benefit, the implied Q4 contribution and the pending Nutrinova sale.
Chemours' profit jump comes with a smaller annual cash forecast
Chemours reported a large profit increase but cut its annual free cash flow forecast. Our comparison separates an insurance-rights payment from the cash outlook.
SBA's per-share target rises as U.S. tower rents fall
SBA's annual AFFO forecast barely changes, but its per-share midpoint rises. We compare the share counts, lower spending assumptions and U.S. tower results.
Healthpeak's lab occupancy gains leave out two new buildings
Healthpeak's reported lab occupancy excludes its newest buildings. Our comparison explains the wider figure, the leasing recovery and which purchases have actually closed.
Upwork is earning more from a smaller marketplace
Upwork's profit rose as its marketplace shrank. Our comparison shows how much of its cost reduction replaced lost gross profit, alongside the completed WorkMotion deal.
Palantir's Q3 sales beat explains 40% of its annual forecast increase
Palantir's Q3 sales beat explains about 40% of its higher annual forecast. We compare what remains for Q4 as U.S. commercial sales overtake U.S. government sales.